科兴制药实控人方减持201.1万股 2020年上市募11亿元

Group 1 - The core point of the news is that Sinovac Biotech (科兴制药) announced a reduction in shareholding by its controlling shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. (科益医药), and its concerted actor, Deng Xueqin, which resulted in a decrease in their combined shareholding from 66.32% to 65.00% [1][2] - The reduction in shareholding was due to the implementation of a previously disclosed share reduction plan and the dilution of shares resulting from the 2022 restricted stock incentive plan [1][2] - The total number of shares held by Keyi Pharmaceutical and Deng Xueqin decreased from 131,778,347 shares to 129,767,472 shares, representing a reduction of 2,010,875 shares, or 1.32% of the total share capital [1][2] Group 2 - The equity change will not lead to a change in the controlling shareholder or actual controller of Sinovac Biotech [2] - Sinovac Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 14, 2020, with an initial public offering (IPO) of 49.6753 million shares at a price of 22.33 yuan per share [2] - The total amount raised from the IPO was 1.109 billion yuan, with a net amount of 999.5 million yuan, which was 710 million yuan less than the originally planned amount of 1.705 billion yuan [2][3]